Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282283 | 0.85 | HCRTR2 (0.60) | HCRTR2HCRTR1METCLK1HTR1A | |
| SCHEMBL8082671 | 0.83 | HCRTR2 (0.51) | SMN1; SMN2HCRTR2HCRTR1METCLK1 | |
| SCHEMBL2282140 | 0.76 | KIT (0.49) | HCRTR2HCRTR1CLK1MAPK1 | |
| SCHEMBL12373197 | 0.73 | HCRTR2 (0.45) | HCRTR2HCRTR1METCLK1MAPK1 | |
| SCHEMBL2277611 | 0.71 | HCRTR2 (0.59) | SMN1; SMN2HCRTR2HCRTR1HTR1AOPRM1 | |
| SCHEMBL3624824 | 0.71 | CLK1 (0.43) | HCRTR2HCRTR1METCLK1AXL | |
| SCHEMBL2279860 | 0.70 | MET (0.43) | HCRTR2HCRTR1METCLK1MAPK1 | |
| SCHEMBL2277917 | 0.70 | HCRTR2 (0.78) | HCRTR2HCRTR1METHTR1AOPRM1 | |
| SCHEMBL8087620 | 0.69 | HCRTR1 (0.55) | SMN1; SMN2HCRTR2HCRTR1HTR1AOPRM1 | |
| SCHEMBL8081046 | 0.69 | HCRTR2 (0.73) | HCRTR2HCRTR1METHTR1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | BERGMAN JEFFREY M (US) | 2011-12-08 | — | — | US | claimed |
| JP-2010535769-A | — | — | 2010-11-25 | — | — | JP | claimed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | claimed |
| EP-2184981-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-05-19 | — | — | EP | claimed |
| WO-2009020642-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | claimed |
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | BERGMAN JEFFREY M (US) | 2011-12-08 | — | — | US | disclosed |
| US-8003797-B2 | Pyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | SMN1; SMN2 2599/4885HCRTR2 1/4885HCRTR1 2/4885 |
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY1R | SMN1; SMN2 2599/4885HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.